title: Disobutamide: a model agent for investigating intracellular drug storage.
abstract: Disobutamide, a bis tertiary amine (pKa1 = 8.6; pKa2 = 10.2) cationic amphiphilic compound, and a putative cardiac antiarrhythmic drug induced clear cytoplasmic vacuoles in dogs and rats. Ultrastructurally, the vacuoles were membrane-bound vesicles containing primarily electron-lucent material. Some concentric lamellar bodies indicative of phospholipidosis were also present. Although numerous vacuoles were seen in one-year toxicity studies in dogs and rats, there was no apparent evidence of necrosis, inflammation, atrophy, hypoplasia, hyperplasia, or metaplasia. Clinical signs or laboratory findings indicative of functional impairment were also not apparent. The picture of the vacuolation in vivo was one of storage. In cultured cells vacuoles were shown to be storage sites for disobutamide and specifically in distended vesicles of the cytoplasmic acidic compartments, such as lysosomes, endocytic, and probably transport vesicles. Storage of the drug in acidic vesicles is compatible with the dibasic nature of the cationic moiety of disobutamide. The intrinsic cell chemicals which accumulate in the vacuoles along with disobutamide remain unknown. Disobutamide may be a useful agent for defining experimentally the borderline between physiologic limits (normal function) and toxicity (functional impairment) in the condition of intracellular drug storage abnormalities and for advancing knowledge of storage mechanisms.
authors: Research and Development, G. D. Searle & Company, Skokie, Illinois 60077.
authors: Z
authors: Z
authors: Ruben
authors: D C
authors: DC
authors: Dodd
authors: K J
authors: KJ
authors: Rorig
authors: S N
authors: SN
authors: Anderson
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000378:metabolism / Q000633:toxicity*; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000187:drug effects / Q000648:ultrastructure; D003470:Culture Media; D003593:Cytoplasm / Q000187:drug effects / Q000648:ultrastructure; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005753:Gastric Mucosa / Q000187:drug effects / Q000648:ultrastructure; D007413:Intestinal Mucosa / Q000187:drug effects / Q000648:ultrastructure; D007668:Kidney / Q000187:drug effects / Q000648:ultrastructure; D008854:Microscopy, Electron / Q000379:methods; D009130:Muscle, Smooth / Q000187:drug effects; D010880:Piperidines / Q000378:metabolism / Q000633:toxicity*; D051381:Rats; D013194:Staining and Labeling; D013329:Structure-Activity Relationship; D014602:Uvea / Q000187:drug effects / Q000648:ultrastructure; D014617:Vacuoles / Q000187:drug effects / Q000648:ultrastructure
chemical_list: D000889:Anti-Arrhythmia Agents; D003470:Culture Media; D010880:Piperidines; C030153:disobutamide